Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K M Tveit

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
The Pharmacogenomics Journal|August 12, 2015
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatinJ B Kjersem, M Thomsen, T Guren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapyJ Hamfjord, T K Guren, O Dajani, et al.
British Journal of Cancer|September 24, 2009
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosisØ Fluge, K Gravdal, E Carlsen, et al.
British Journal of Cancer|October 27, 2012
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancerM P Myklebust, Z Li, T H Tran, et al.
Human Mutation|March 3, 1998
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screeningT I Andersen, H G Eiken, F Couch, et al.
Human Mutation|January 1, 1997
Screening for ESR mutations in breast and ovarian cancer patientsT I Anderson, R Wooster, K Laake, et al.
British Journal of Cancer|September 24, 2004
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancerN E Schoemaker, I E L M Kuppens, V Moiseyenko, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
The Pharmacogenomics Journal|August 12, 2015
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatinJ B Kjersem, M Thomsen, T Guren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapyJ Hamfjord, T K Guren, O Dajani, et al.
British Journal of Cancer|September 24, 2009
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosisØ Fluge, K Gravdal, E Carlsen, et al.
British Journal of Cancer|October 27, 2012
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancerM P Myklebust, Z Li, T H Tran, et al.
Human Mutation|March 3, 1998
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screeningT I Andersen, H G Eiken, F Couch, et al.
Human Mutation|January 1, 1997
Screening for ESR mutations in breast and ovarian cancer patientsT I Anderson, R Wooster, K Laake, et al.
British Journal of Cancer|September 24, 2004
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancerN E Schoemaker, I E L M Kuppens, V Moiseyenko, et al.
Pageof 8